Story perspectives

FDA Approves Updated COVID Vaccines for High-Risk Patients

8/28/2026

Summary

Story summary

The FDA approved COVID-19 vaccines for high-risk patients on August 27, 2026.
Eligibility stays limited to adults 65 plus and younger people with a high-risk condition.
Pfizer’s Comirnaty XFG was authorized for adults 65 plus and ages 5-64 with a condition.
Moderna’s Spikevax XFG and mNEXSPIKE XFG were approved for high-risk people ages 6 months-64 and 12-64, respectively.
The CDC advisory panel that sets eligibility is in limbo after a court invalidated appointments, leaving coverage uncertain.

1 of 1

Story summary

The FDA approved COVID-19 vaccines for high-risk patients on August 27, 2026.
Eligibility stays limited to adults 65 plus and younger people with a high-risk condition.
Pfizer’s Comirnaty XFG was authorized for adults 65 plus and ages 5-64 with a condition.
Moderna’s Spikevax XFG and mNEXSPIKE XFG were approved for high-risk people ages 6 months-64 and 12-64, respectively.
The CDC advisory panel that sets eligibility is in limbo after a court invalidated appointments, leaving coverage uncertain.